RCH 01

Drug Profile

RCH 01

Alternative Names: DSC cell therapy - RepliCel; Hair cell replacement therapy - RepliCel; RCH-01; RepliCel; RepliCel Hair-01

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator RepliCel Life Sciences
  • Developer RepliCel Life Sciences; Shiseido
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Alopecia

Most Recent Events

  • 26 Sep 2016 Clinical trials in Alopecia in Japan (Intradermal)
  • 21 Jul 2016 Pharmaceuticals and Medical Devices Agency, Japan approves clinical trial application for RCH 01 in Alopecia
  • 21 Jul 2016 Shiseido plans a phase II trial for Alopecia in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top